Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 41 entries
Sorted by: Best Match Show Resources per page
Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.

Cancer biology & therapy

Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R.
PMID: 30339521
Cancer Biol Ther. 2019;20(2):219-226. doi: 10.1080/15384047.2018.1523849. Epub 2018 Oct 19.

Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer, as...

Cite
Ikeda S, Elkin SK, Tomson BN, et al. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2018;20(2):219-226doi: 10.1080/15384047.2018.1523849.
Ikeda, S., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2019). Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer biology & therapy, 20(2), 219-226. https://doi.org/10.1080/15384047.2018.1523849
Ikeda, Sadakatsu, et al. "Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing." Cancer biology & therapy vol. 20,2 (2019): 219-226. doi: https://doi.org/10.1080/15384047.2018.1523849
Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019;20(2):219-226. doi: 10.1080/15384047.2018.1523849. Epub 2018 Oct 19. PMID: 30339521; PMCID: PMC6343723.
Copy Download .nbib Format: NLM
Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013;64:941-50.

European urology

Sampson N, Berger P, Klocker H.
PMID: 24565966
Eur Urol. 2014 Jun;65(6):e102-3. doi: 10.1016/j.eururo.2014.01.038. Epub 2014 Feb 10.

No abstract available.

Cite
Sampson N, Berger P, Klocker H. Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013;64:941-50. Eur Urol. 2014;65(6):e102-3doi: 10.1016/j.eururo.2014.01.038.
Sampson, N., Berger, P., & Klocker, H. (2014). Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013;64:941-50. European urology, 65(6), e102-3. https://doi.org/10.1016/j.eururo.2014.01.038
Sampson, Natalie, et al. "Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013;64:941-50." European urology vol. 65,6 (2014): e102-3. doi: https://doi.org/10.1016/j.eururo.2014.01.038
Sampson N, Berger P, Klocker H. Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013;64:941-50. Eur Urol. 2014 Jun;65(6):e102-3. doi: 10.1016/j.eururo.2014.01.038. Epub 2014 Feb 10. PMID: 24565966.
Copy Download .nbib Format: NLM
Intraductal carcinoma of the prostate: the whole story.

Pathology

Zhou M.
PMID: 24018805
Pathology. 2013 Oct;45(6):533-9. doi: 10.1097/PAT.0b013e3283653322.

Intraductal carcinoma of the prostate (IDC-P) is characterised by proliferation of malignant secretory cells that markedly expand prostatic ducts and acini. Its morphological features and diagnostic criteria have been refined in recent studies. Its molecular characteristics have also been...

Cite
Zhou M. Intraductal carcinoma of the prostate: the whole story. Pathology. 2013;45(6):533-9doi: 10.1097/PAT.0b013e3283653322.
Zhou, M. (2013). Intraductal carcinoma of the prostate: the whole story. Pathology, 45(6), 533-9. https://doi.org/10.1097/PAT.0b013e3283653322
Zhou, Ming. "Intraductal carcinoma of the prostate: the whole story." Pathology vol. 45,6 (2013): 533-9. doi: https://doi.org/10.1097/PAT.0b013e3283653322
Zhou M. Intraductal carcinoma of the prostate: the whole story. Pathology. 2013 Oct;45(6):533-9. doi: 10.1097/PAT.0b013e3283653322. PMID: 24018805.
Copy Download .nbib Format: NLM
MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR).

Journal of visualized experiments : JoVE

Gordanpour A, Nam RK, Sugar L, Bacopulos S, Seth A.
PMID: 22643910
J Vis Exp. 2012 May 16;(63):e3874. doi: 10.3791/3874.

MicroRNAs (miRNAs) are single-stranded, 18-24 nucleotide long, non-coding RNA molecules. They are involved in virtually every cellular process including development, apoptosis, and cell cycle regulation. MiRNAs are estimated to regulate the expression of 30% to 90% of human genes...

Cite
Gordanpour A, Nam RK, Sugar L, et al. MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR). J Vis Exp. 2012;(63):e3874doi: 10.3791/3874.
Gordanpour, A., Nam, R. K., Sugar, L., Bacopulos, S., & Seth, A. (2012). MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR). Journal of visualized experiments : JoVE, (63), e3874. https://doi.org/10.3791/3874
Gordanpour, Aida, et al. "MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR)." Journal of visualized experiments : JoVE vol. ,63 (2012): e3874. doi: https://doi.org/10.3791/3874
Gordanpour A, Nam RK, Sugar L, Bacopulos S, Seth A. MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR). J Vis Exp. 2012 May 16;(63):e3874. doi: 10.3791/3874. PMID: 22643910; PMCID: PMC3466958.
Copy Download .nbib Format: NLM
Recurrent gene fusions in prostate cancer.

Nature reviews. Cancer

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.
PMID: 18563191
Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19.

The discovery of recurrent gene fusions in a majority of prostate cancers has important clinical and biological implications in the study of common epithelial tumours. Gene fusion and chromosomal rearrangements were previously thought to be primarily the oncogenic mechanism...

Cite
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497-511doi: 10.1038/nrc2402.
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008). Recurrent gene fusions in prostate cancer. Nature reviews. Cancer, 8(7), 497-511. https://doi.org/10.1038/nrc2402
Kumar-Sinha, Chandan, et al. "Recurrent gene fusions in prostate cancer." Nature reviews. Cancer vol. 8,7 (2008): 497-511. doi: https://doi.org/10.1038/nrc2402
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19. PMID: 18563191; PMCID: PMC2711688.
Copy Download .nbib Format: NLM
'Working toward understanding oligo and polymetastatic prostate cancer'.

Current opinion in urology

Chapin BF, Bellmunt J.
PMID: 28922341
Curr Opin Urol. 2017 Nov;27(6):532. doi: 10.1097/MOU.0000000000000451.

No abstract available.

Cite
Chapin BF, Bellmunt J. 'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017;27(6):532doi: 10.1097/MOU.0000000000000451.
Chapin, B. F., & Bellmunt, J. (2017). 'Working toward understanding oligo and polymetastatic prostate cancer'. Current opinion in urology, 27(6), 532. https://doi.org/10.1097/MOU.0000000000000451
Chapin, Brian F, and Bellmunt, Joaquim. "'Working toward understanding oligo and polymetastatic prostate cancer'." Current opinion in urology vol. 27,6 (2017): 532. doi: https://doi.org/10.1097/MOU.0000000000000451
Chapin BF, Bellmunt J. 'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 Nov;27(6):532. doi: 10.1097/MOU.0000000000000451. PMID: 28922341.
Copy Download .nbib Format: NLM
Genetic predisposition to prostate cancer: Update and future perspectives.

Urologic oncology

Demichelis F, Stanford JL.
PMID: 24996773
Urol Oncol. 2015 Feb;33(2):75-84. doi: 10.1016/j.urolonc.2014.04.021. Epub 2014 Jul 02.

OBJECTIVE: Prostate cancer is the second most frequent cancer in men worldwide and kills over 250,000 men worldwide every year. Prostate cancer is a heterogeneous disease at the clinical and the molecular level. The Scandinavian Twin Registry Study demonstrated...

Cite
Demichelis F, Stanford JL. Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol. 2014;33(2):75-84doi: 10.1016/j.urolonc.2014.04.021.
Demichelis, F., & Stanford, J. L. (2015). Genetic predisposition to prostate cancer: Update and future perspectives. Urologic oncology, 33(2), 75-84. https://doi.org/10.1016/j.urolonc.2014.04.021
Demichelis, Francesca, and Stanford, Janet L. "Genetic predisposition to prostate cancer: Update and future perspectives." Urologic oncology vol. 33,2 (2015): 75-84. doi: https://doi.org/10.1016/j.urolonc.2014.04.021
Demichelis F, Stanford JL. Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol. 2015 Feb;33(2):75-84. doi: 10.1016/j.urolonc.2014.04.021. Epub 2014 Jul 02. PMID: 24996773.
Copy Download .nbib Format: NLM
Identifying an ERG-positive subclass with clinical progression using expression profiling.

European urology

Sboner A, Rubin MA.
PMID: 23557717
Eur Urol. 2013 Dec;64(6):951-2. doi: 10.1016/j.eururo.2013.03.036. Epub 2013 Mar 26.

No abstract available.

Cite
Sboner A, Rubin MA. Identifying an ERG-positive subclass with clinical progression using expression profiling. Eur Urol. 2013;64(6):951-2doi: 10.1016/j.eururo.2013.03.036.
Sboner, A., & Rubin, M. A. (2013). Identifying an ERG-positive subclass with clinical progression using expression profiling. European urology, 64(6), 951-2. https://doi.org/10.1016/j.eururo.2013.03.036
Sboner, Andrea, and Rubin, Mark A. "Identifying an ERG-positive subclass with clinical progression using expression profiling." European urology vol. 64,6 (2013): 951-2. doi: https://doi.org/10.1016/j.eururo.2013.03.036
Sboner A, Rubin MA. Identifying an ERG-positive subclass with clinical progression using expression profiling. Eur Urol. 2013 Dec;64(6):951-2. doi: 10.1016/j.eururo.2013.03.036. Epub 2013 Mar 26. PMID: 23557717.
Copy Download .nbib Format: NLM
Clinical uncertainty of prostate cancer genetic risk panels.

Science translational medicine

Pomerantz M, Freedman ML.
PMID: 23616119
Sci Transl Med. 2013 Apr 24;5(182):182ed6. doi: 10.1126/scitranslmed.3004696.

No abstract available.

Cite
Pomerantz M, Freedman ML. Clinical uncertainty of prostate cancer genetic risk panels. Sci Transl Med. 2013;5(182):182ed6doi: 10.1126/scitranslmed.3004696.
Pomerantz, M., & Freedman, M. L. (2013). Clinical uncertainty of prostate cancer genetic risk panels. Science translational medicine, 5(182), 182ed6. https://doi.org/10.1126/scitranslmed.3004696
Pomerantz, Mark, and Freedman, Matthew L. "Clinical uncertainty of prostate cancer genetic risk panels." Science translational medicine vol. 5,182 (2013): 182ed6. doi: https://doi.org/10.1126/scitranslmed.3004696
Pomerantz M, Freedman ML. Clinical uncertainty of prostate cancer genetic risk panels. Sci Transl Med. 2013 Apr 24;5(182):182ed6. doi: 10.1126/scitranslmed.3004696. PMID: 23616119.
Copy Download .nbib Format: NLM
Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer.

Sleep

Sun X, Ye D, Jiang M, Qian Y, Mao Y.
PMID: 33878190
Sleep. 2021 Oct 11;44(10). doi: 10.1093/sleep/zsab104.

STUDY OBJECTIVES: Observational epidemiological studies have suggested that chronotype may play a role in the pathogenesis and progression of prostate cancer. However, whether there is a causal association remains unknown. The aim of the present study was to examine...

Cite
Sun X, Ye D, Jiang M, et al. Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer. Sleep. 2021;44(10)doi: 10.1093/sleep/zsab104.
Sun, X., Ye, D., Jiang, M., Qian, Y., & Mao, Y. (2021). Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer. Sleep, 44(10), . https://doi.org/10.1093/sleep/zsab104
Sun, Xiaohui, et al. "Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer." Sleep vol. 44,10 (2021). doi: https://doi.org/10.1093/sleep/zsab104
Sun X, Ye D, Jiang M, Qian Y, Mao Y. Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer. Sleep. 2021 Oct 11;44(10). doi: 10.1093/sleep/zsab104. PMID: 33878190.
Copy Download .nbib Format: NLM
[Bioinformatics-based identification of the key genes associated with prostate cancer].

Zhonghua nan ke xue = National journal of andrology

Zhao HB, Xu GB, Yang WQ, Li XZ, Chen SX, Gan Y, Su ZM, Sheng M, Zeng YR.
PMID: 34914287
Zhonghua Nan Ke Xue. 2021 Jun;27(6):489-498.

OBJECTIVE: To identify the key genes associated with the pathogenesis of PCa using the bioinformatics approach for a deeper insight into the molecular mechanisms underlying the development and progression of PCa.METHODS: The microarray datasets GSE70770, GSE32571 and GSE46602 were...

Cite
Zhao HB, Xu GB, Yang WQ, et al. [Bioinformatics-based identification of the key genes associated with prostate cancer]. Zhonghua Nan Ke Xue. 2021;27(6):489-498
Zhao, H. B., Xu, G. B., Yang, W. Q., Li, X. Z., Chen, S. X., Gan, Y., Su, Z. M., Sheng, M., & Zeng, Y. R. (2021). [Bioinformatics-based identification of the key genes associated with prostate cancer]. Zhonghua nan ke xue = National journal of andrology, 27(6), 489-498.
Zhao, Hai-Bo, et al. "[Bioinformatics-based identification of the key genes associated with prostate cancer]." Zhonghua nan ke xue = National journal of andrology vol. 27,6 (2021): 489-498.
Zhao HB, Xu GB, Yang WQ, Li XZ, Chen SX, Gan Y, Su ZM, Sheng M, Zeng YR. [Bioinformatics-based identification of the key genes associated with prostate cancer]. Zhonghua Nan Ke Xue. 2021 Jun;27(6):489-498. Chinese. PMID: 34914287.
Copy Download .nbib Format: NLM
What is the significance of race to prostate carcinoma?.

Cancer

Bostwick DG.
PMID: 10463964
Cancer. 1999 Sep 01;86(5):735-7. doi: 10.1002/(sici)1097-0142(19990901)86:5<735::aid-cncr1>3.0.co;2-r.

No abstract available.

Cite
Bostwick DG. What is the significance of race to prostate carcinoma?. Cancer. 1999;86(5):735-7doi: 10.1002/(sici)1097-0142(19990901)86:5<735::aid-cncr1>3.0.co;2-r.
Bostwick, D. G. (1999). What is the significance of race to prostate carcinoma?. Cancer, 86(5), 735-7. https://doi.org/10.1002/(sici)1097-0142(19990901)86:5<735::aid-cncr1>3.0.co;2-r
Bostwick, D G. "What is the significance of race to prostate carcinoma?." Cancer vol. 86,5 (1999): 735-7. doi: https://doi.org/10.1002/(sici)1097-0142(19990901)86:5<735::aid-cncr1>3.0.co;2-r
Bostwick DG. What is the significance of race to prostate carcinoma?. Cancer. 1999 Sep 01;86(5):735-7. doi: 10.1002/(sici)1097-0142(19990901)86:5<735::aid-cncr1>3.0.co;2-r. PMID: 10463964.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 41 entries